Pilot Study of the Ablative Fractional CO2 Laser in Hypertrophic Scars in Adult Burn Patients
- Conditions
- Burns
- Interventions
- Procedure: Laser treatment
- Registration Number
- NCT03240718
- Lead Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
- Brief Summary
This is a randomized, controlled, within-patient, single-blinded, pilot study that will evaluate the impact of laser treatment on burn HSc relative to self-matched control scars. The studied primary outcomes of treatment are scar pliability, thickness, vascularity, pain, itch and patient satisfaction.
- Detailed Description
Prior to treatment initiation, two independent scars sites will be selected and an anatomically- on each individual. At the selected treatment site the scar will be treated with the CORE fractional CO2 laser Participants will receive 3 treatment sessions scheduled 4 weeks apart. The scar sites will be evaluated at baseline, immediately before the 3rd treatment and 12 weeks after their final treatment session.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
- Fitzpatrick skin type <IV (37),
- Have sustained a thermal burn injury,
- Have at least 2 independent sites that show clinical evidence of HSc,
- Are 2 months or more post-injury.
- Subjects with skin phototypes IV or higher,
- With history of keloidal scarring,
- Who have coagulation disorder,
- Are taking immunosuppressive medications,
- If the mechanism of injury is an electrical, chemical, or cold injury,
- Any underlying active skin disease,
- Have taken oral Isotreinoin within the last 6 months,
- Photosensitivity or have taken photosensitizing medications,
- Pregnancy,
- Previous treatment with dermabrasion, chemical peel, laser or intense pulsed light treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Laser treated HSc scar Laser treatment Co2 laser treatment
- Primary Outcome Measures
Name Time Method Skin Characteristics changes baseline, 12 weeks and 24 weeks Erythema, elasticity and thickness measures
- Secondary Outcome Measures
Name Time Method Satisfaction Questionnaire baseline, 24 weeks Questionnaire